Studies have shown that active fund managers routinely underperform the S&P500 index*​

NervGen Pharma Corp. (NASDAQ: NGEN)

NGEN Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
371.20%

NGEN Stock Analysis

NGEN PE Ratio:

NGEN PEG Ratio: Not Available

NGEN Forward EPS Growth (12 month): 0.00%

NGEN PS Ratio:

NGEN PSG Ratio: Not Available

NGEN Forward Revenue Growth (12 month): 0.00%

NGEN Articles

No data was found